|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Resistance mechanisms in the androgen receptor (AR) signaling pathway remain key drivers in the progression to castration-resistant prostate cancer (CRPC) and relapse under antihormonal therapy.
|
29366632 |
2018 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this network, a subset of 35 "AR-signature" genes were highly co-expressed with AR (;CC;>0.6) that included transcriptional regulators PATZ1, NFATC4, and SPDEF.
|
25447311 |
2015 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since Sam68 is implicated in a number of signalling pathways, we reasoned that its role in PCa may involve modulation of the androgen receptor (AR) signalling cascade, which drives the onset and progression of PCa.
|
18273831 |
2008 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As PCa is hormone dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease.
|
30306781 |
2018 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The promotion and progression of prostate cancer (PCa) are associated with androgen receptor (AR) signalling.
|
18037965 |
2008 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have discovered two different point mutations in a single codon of the X-linked androgen-receptor (AR) gene in two pairs of unrelated families who have complete androgen insensitivity (resistance) associated with different AR phenotypes in their genital skin fibroblasts.
|
1609793 |
1992 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The enzyme 5α-reductase, which converts testosterone to dihydrotestosterone (DHT), performs key functions in the androgen receptor (AR) signaling pathway.
|
22194926 |
2011 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we demonstrate that an expanded p63<sup>+</sup> and CK5<sup>+</sup> basal/progenitor cell population, induced by the concomitant activation of oncogenic Kras(G12D) and androgen receptor (AR) signaling, underwent cell differentiation in vivo The differentiation process led to suppression of p63-expressing cells with a decreased number of CK5<sup>+</sup> basal cells but an increase of CK8<sup>+</sup> luminal tumorigenic cells and revealed a hierarchal lineage pattern consisting of p63<sup>+</sup>/CK5<sup>+</sup> progenitor, CK5<sup>+</sup>/CK8<sup>+</sup> transitional progenitor, and CK8<sup>+</sup> differentiated luminal cells.
|
27760825 |
2016 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several mechanisms that enhance AR signalling in an androgen-depleted environment have been elucidated: (1) AR mutations that allow activation by low androgen levels or by other endogenous steroids, (2) AR amplification and/or overexpression, (3) increased local intracrine synthesis of androgens, (4) changes in AR cofactors and (5) cross-talk with cytokines and growth factors.
|
19155198 |
2009 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the involvement of the prostate androgen-regulated (PAR) gene in the androgen receptor (AR) signaling pathway and the malignant phenotype of androgen-independent prostate cancer (PCa) cells.
|
16763722 |
2006 |
|
Aortic Valve Insufficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A better understanding in the complexity of the androgen receptor (AR) signalling pathway has highlighted that this form of treatment is not sufficient.
|
21130868 |
2011 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite the initial response, patients typically relapse with a more aggressive form described as castration-resistant prostate cancer (CRCP), driven by continued androgen receptor (AR) signaling.
|
21426013 |
2010 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging preclinical evidence suggests that androgen-mediated androgen receptor (AR) signals promote bladder cancer progression.
|
27330033 |
2016 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate a role of RNase L as a suppressor of androgen receptor (AR) signaling, cell migration and matrix metalloproteinase activity.
|
28257035 |
2017 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling remains the major oncogenic pathway in prostate cancer (PCa).
|
28275218 |
2017 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Men that succumb to PCa have a disease that is resistant to hormonal therapies that suppress androgen receptor (AR) signaling, which plays a central role in tumor development and progression.
|
25934687 |
2015 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Integration of cellular signaling pathways with androgen receptor (AR) signaling can be achieved through phosphorylation of AR by cellular kinases.
|
22986532 |
2013 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signals play a decisive role in regulating the growth and differentiation of both normal and cancerous prostate cells by triggering the regulation of target genes, in a process in which AR cofactors have critical functions.
|
15604291 |
2004 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signalling in fibroblasts is important in prostate development and carcinogenesis, and is inversely related to prostate cancer mortality.
|
27634452 |
2017 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, mounting evidence indicates that androgen receptor (AR) signaling continues to play a critical role in the growth of advanced prostate cancer despite androgen deprivation.
|
23386686 |
2013 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the role of NF-κB in the development and progression of urothelial cancer as well as cross-talk between NF-κB and androgen receptor (AR) signals in urothelial cells.
|
29592878 |
2018 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Function of <i>HSD17B2</i> in steroidogenesis, androgen receptor (AR) signaling, and tumor growth was investigated with prostate cancer cell lines and a xenograft model.
|
30228209 |
2019 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
From the inception of clinical efforts to suppress androgen receptor (AR) signaling by reducing AR ligands, it was also recognized that administration of T in men with castration-resistant prostate cancer (CRPC) could result in substantial clinical responses.
|
29210989 |
2017 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current treatments for castration-resistant prostate cancer (CRPC) that target androgen receptor (AR) signaling improve patient survival, yet ultimately fail.
|
28411207 |
2017 |
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling is regarded as the driving force in prostate carcinogenesis, and its modulation represents a logical target for prostate cancer (PC) prevention and treatment.
|
22592999 |
2013 |